新辅助化疗增加HR+/HER2-乳腺癌基因组放疗抵抗:对RSI/GARD指导个体化放疗的意义
该研究分析两个公共队列中接受新辅助化疗的HR+/HER2-乳腺癌患者匹配的疗前疗后RNA测序数据,用10基因秩次模型计算放疗敏感性指数(RSI)。结果显示化疗后RSI reproducibly升高,提示残留肿瘤在基因组层面可能更抗拒放疗,并导致不同分割方案下基因组调整放疗剂量(GARD)的异质性变化。
要点
- 新辅助化疗后HR+/HER2-乳腺癌RSI升高,提示残留病灶基因组放疗抵抗增强。
- 疗前M2巨噬细胞比例越高,RSI变化幅度越大。
- 化疗后RSI变化可致不同分割方案下GARD剂量调整出现异质性。
核心结论
- 新辅助化疗与HR+/HER2-乳腺癌RSI可重复性升高相关,提示残留肿瘤在基因组层面可能变得更抗拒放疗。
- 化疗后RSI值得前瞻性评估,以指导个体化辅助放疗策略。
研究设计与样本
- 分析两个公共队列中接受新辅助化疗的HR+/HER2-乳腺癌患者匹配的疗前与疗后RNA测序数据。
- 发现队列来自GSE191127,含16对匹配样本;验证队列来自GSE309004,含14对匹配HR+/HER2-样本。
- RSI采用10基因秩次模型计算,ΔRSI定义为RSI_post减RSI_pre。
- 免疫分数用quanTIseq推断,GARD按START B、RTOG 1005和FAST-Forward辅助放疗方案计算。
主要发现
- 发现队列平均RSI从0.602升至0.677,16例中12例(75%)化疗后升高。
- 验证队列平均RSI从0.489升至0.593(Wilcoxon P = .014),14例中11例(78.6%)升高。
- 汇总队列平均ΔRSI为+0.089,30例中23例(76.7%)化疗后RSI升高(Wilcoxon P = .005)。
- 疗前M2巨噬细胞分数越高,ΔRSI越大。
- RSI变化在不同分割方案下转化为异质性的GARD剂量调整。
关键数值与推荐
- RSI采用10基因秩次模型计算。
- ΔRSI定义为RSI_post - RSI_pre。
- GARD按START B、RTOG 1005和FAST-Forward辅助放疗方案计算。
- 验证队列RSI升高Wilcoxon P = .014;汇总队列Wilcoxon P = .005。
临床怎么用
- 对HR+/HER2-乳腺癌新辅助化疗后残留病灶,疗前活检RSI可能不能代表辅助放疗靶区的基因组放疗敏感性。
- 化疗后RSI可考虑用于前瞻性评估个体化辅助放疗策略,但尚未进入常规实践。
局限性
- 研究基于两个公共队列的匹配RNA测序数据,发现队列16对、验证队列14对,样本量有限。
- 化疗后RSI升高与GARD调整的临床获益尚未在前瞻性研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adjuvant radiation therapy (RT) improves locoregional control after breast cancer surgery, but dose prescription remains based mainly on clinicopathologic risk rather than individual tumor radiosensitivity. The radiation sensitivity index (RSI) and genomic-adjusted radiation dose (GARD) provide a framework for biologically guided radiation therapy personalization. In the neoadjuvant setting, however, radiosensitivity measured on the diagnostic biopsy may not reflect the residual disease ultimately targeted by adjuvant radiation therapy. METHODS AND MATERIALS: We analyzed matched pretreatment and posttreatment RNA sequencing data from 2 public cohorts of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer treated with neoadjuvant chemotherapy. The discovery cohort included 16 matched pairs from GSE191127, and the validation cohort included 14 matched HR+/HER2- pairs from GSE309004. The RSI was computed using a 10-gene rank-based model. The ΔRSI was defined as RSI_post - RSI_pre. Immune fractions were inferred using quanTIseq, and the GARD was calculated for START B, RTOG 1005, and FAST-Forward adjuvant radiation therapy schedules. RESULTS: In the discovery cohort, the mean RSI increased from 0.602 to 0.677 after neoadjuvant chemotherapy, with 12 of 16 patients (75%) showing a posttreatment increase. In the validation cohort, the mean RSI increased from 0.489 to 0.593 (Wilcoxon P = .014), with 11 of 14 patients (78.6%) showing an increase. In the pooled cohort, the mean ΔRSI was +0.089, and 23 of 30 patients (76.7%) showed an increased RSI after chemotherapy (Wilcoxon P = .005). Higher pretreatment M2 macrophage fraction correlated with a larger ΔRSI. The RSI changes translated into heterogeneous GARD dose modifications across fractionation schedules. CONCLUSIONS: Neoadjuvant chemotherapy is associated with a reproducible increase in RSI in HR+/HER2- breast cancer, suggesting that residual tumors may become more radioresistant at the genomic level after systemic therapy. A postneoadjuvant chemotherapy RSI warrants prospective evaluation for individualized adjuvant radiation therapy strategies.
引用
- Loap P, Crehange G, Kirova Y, et al. Neoadjuvant Chemotherapy Increases Genomic Radioresistance in Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Implications for Radiation Sensitivity Index/Genomic-Adjusted Radiation Dose-Guided Radiation Therapy Personalization. Adv Radiat Oncol. 2026. PMID: 42936472. doi:10.1016/j.adro.2026.102174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。